TxPredictor for Cell Therapy

About Pirche

Pirche AG is a private, Leipzig-based company developing a sophisticated software platform for immunological risk assessment in transplantation and cell therapy. Its technology moves beyond traditional HLA matching to epitope-level analysis, aiming to minimize graft rejection and graft-versus-host disease. The company appears to be in a commercial or late-validation stage with its TxPredictor platform, which is integrated with major HLA lab software and is backed by extensive clinical validation across over 250,000 cases. Pirche is currently running a funding campaign to support its growth in the digital health and precision medicine space.

Therapeutic Areas